Immuron (IMRN) Non-Current Assets (2016 - 2025)
Immuron's quarterly Non-Current Assets came in at $1146.2 in Q3 2025, down 86.08% year-on-year from $8236.3 in Q3 2024, and down 98.44% quarter-over-quarter from $73403.9 in Q2 2025.
Immuron has reported Non-Current Assets for 10 years, with the latest figure at $1146.2 in Q3 2025.
- For the quarter ending Q3 2025, Non-Current Assets fell 86.08% year-over-year to $1146.2; the trailing twelve-month figure through Sep 2025 stood at $1146.2 (down 86.08% YoY), and the FY2025 full-year result was $1146.2, down 86.08% from the prior year.
- Non-Current Assets for Q3 2025 stood at $1146.2, down from $73403.9 in the prior quarter.
- The five-year high for Non-Current Assets was $1.1 million in Q2 2023, with the low at $1146.2 in Q3 2025.
- Average Non-Current Assets over 5 years is $398684.8, with a median of $172204.7 recorded in 2025.
- Peak annual rise in Non-Current Assets reached 8814.95% in 2023, while the deepest fall reached 99.22% in 2023.
- Tracing IMRN's Non-Current Assets over 5 years: stood at $947289.9 in 2021, then declined by 17.9% to $777698.3 in 2022, then plunged by 99.22% to $6093.8 in 2023, then jumped by 4347.25% to $271005.5 in 2024, then plunged by 99.58% to $1146.2 in 2025.
- The last three Non-Current Assets figures came in at $1146.2 (Q3 2025), $73403.9 (Q2 2025), and $271005.5 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | 1,146.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 1,146.16 |
| Jun 30, 2025 | 73,403.89 |
| Dec 31, 2024 | 271,005.50 |
| Sep 9, 2024 | 8,236.32 |
| Jun 30, 2024 | 542,793.65 |
| Dec 31, 2023 | 6,093.77 |
| Sep 28, 2023 | 1.03 Mn |
| Aug 30, 2023 | 15,788.45 |
| Jun 30, 2023 | 1.06 Mn |
| Dec 31, 2022 | 777,698.31 |
| Aug 31, 2022 | 823,152.59 |
| Jun 30, 2022 | 11,836.72 |
| Dec 31, 2021 | 947,289.90 |
| Jun 30, 2021 | 13,003.28 |
| Dec 31, 2020 | 17,780.76 |
| Sep 1, 2020 | 1.79 Mn |
| Jun 30, 2020 | 1.18 Mn |
| Dec 31, 2019 | 17,931.22 |
| Jun 30, 2019 | 1.32 Mn |
| Dec 31, 2018 | 2.19 Mn |
| Sep 27, 2018 | 1.60 Mn |
| Aug 30, 2018 | 2.19 Mn |
| Jun 30, 2018 | 1.66 Mn |
| Dec 31, 2017 | 14,680.48 |
| Sep 28, 2017 | 14,856.79 |
| Aug 31, 2017 | 18,837.00 |
| Jun 30, 2017 | 14,150.55 |
| Dec 31, 2016 | 13,619.11 |